Cardiology

Find out if this drug can prolong survival if given earlier in the course of disease.

Dr. Barret Bulmer examines a handy tool for your iPhone that lets you record ECGs.

Researchers evaluated this assay in 155 asymptomatic Doberman pinschers to determine whether it can be used as an indicator for this life-threatening condition.

Dr. Heather Lewellen reports on how a recent cardiology workshop demonstrated how heart disease and heart failure don't change, but the way we treat and manage them changes constantly.

Find out the latest on this cardiac biomarker.

Sharing personal stories of pet illness in exam rooms, veterinary newsletters and emails can bridge the gap between a seemingly trouble-free veterinarian and scared clients.

Was this dog's tooth root abscess the cause of its severe, progressive systemic illness?

Can this screening test help identify this silent killer in cats?

Studies have been performed in humans to determine if early administration of ACE inhibitors to human patients with ischemic dilated cardiomyopathy decreases the progression of myocardial failure and so reduces mortality.

There currently is no evidence that any drug alters the natural history of hypertrophic cardiomyopathy (HCM) in cats until they are in heart failure.

Dilated cardiomyopathy (DCM) is a cardiac disease due to an inherent abnormality in the myocardium that results in a decrease in myocardial contractility (i.e., myocardial failure) and is not secondary to another primary disease.

In humans, the familial nature of HCM was first reported in 1958. It has been demonstrated that over 70% of human cases of HCM are inherited in an autosomal dominant pattern, with most other cases being sporadic (although often still genetic in origin).

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease that primarily affects left ventricular (LV) myocardium and is characterized by mild to severe thickening (concentric hypertrophy) of the LV wall (septum and/or free wall) and papillary muscles.

Small animal patients with cardiac disease and/or congenital abnormalities can be challenging and sometimes intimidating patients.

The gold standard for determining arterial blood gas levels is actually measuring arterial blood samples with a blood gas machine to get information on the arterial oxygen partial pressure (PaO2), pH and carbon dioxide partial pressure (PaCO2).

The biomarker can help assess patients with cardiac and respiratory disease.

Don't wait until it becomes a more serious problem. Start educating your clients about heart disease today.

Dr. Jennifer Garcia helps ensure you're measuring blood pressure correctly in your patients.

Understanding this syndrome's pathophysiology and classification schemes will help you better manage affected patients.

Once a death sentence, canine pulmonary hypertension no longer carries such a grave prognosis.

About 70 percent of dogs affected by mitral valve disease do not develop heart failure or die as a result.

Congenital heart disease (CHD) is a morphologic defect of the heart or great vessels which is present at birth. "Congenital" does not imply the defect was inherited, although many CHD are heritable. CHD may also be caused by de novo spontaneous mutations, which have the potential to be transmitted to progeny. Diagnosis of CHD is important for the health of the patient and also to eliminate affected individuals from the breeding pool.

The primary indication for obtaining an electrocardiogram (ECG) is to evaluate an arrhythmia. Patients with a history of syncope, episodic weakness, or collapse should be evaluated with an ECG. An ECG is an insensitive test for assessment of specific cardiac chamber enlargement, and interpretation of structural heart disease is best done using radiography and echocardiography.

Collapse and shock are a clinical manifestation of many different severe diseases, and requires emergency triage and care. Other dogs may present with a history of episodes of collapse and may be clinically stable on presentation. These two categories of patients are treated very differently, but they have some similar differential diagnoses.

Pericardial effusion is a fairly common acquired heart disease in dogs, and prevalence has been reported to be 0.43% (or 1 dog per 233 cases) of dogs presenting to a referral veterinary hospital, and accounts for approximately 7% of dogs with clinical signs of cardiac disease.1